Can Ozempic Help with Fertility? What You Need to Know

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 receptor agonists like semaglutide have transformed weight management, but patients planning pregnancy often ask whether these medications support or harm fertility. Research shows that modest weight loss typically improves ovulation and menstrual regularity in people with obesity-related infertility, yet semaglutide's direct effects on reproductive hormones remain an active area of clinical study.

How Weight Loss Improves Fertility Outcomes

Obesity disrupts hormonal balance in ways that directly interfere with reproduction. Excess adipose tissue produces inflammatory molecules that can suppress ovulation, reduce egg quality, and lower sperm production. Studies demonstrate that losing just 5–10% of body weight can restore regular menstrual cycles and significantly increase pregnancy rates in people with polycystic ovary syndrome (PCOS), a condition affecting up to 15% of reproductive-age individuals.

When semaglutide facilitates weight loss, it removes a major biological barrier to fertility. The reduction in visceral fat decreases insulin resistance, which is central to PCOS pathology. Improved insulin sensitivity, in turn, lowers androgen levels—a key driver of anovulation (failure to ovulate). For many patients, this metabolic reset creates conditions where natural conception becomes possible again.

Semaglutide's Direct Effects on Reproductive Hormones

GLP-1 receptors are expressed throughout the hypothalamus and pituitary gland, regions that control reproductive hormone release. While semaglutide's primary action targets glucose homeostasis and appetite, its presence in these neuroendocrine centers raises legitimate questions about off-target effects on luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estrogen signaling. Current evidence suggests these direct effects are modest compared to the systemic benefits of weight reduction.

Animal studies indicate that acute GLP-1 agonist exposure can transiently alter LH pulsatility, but human trials in women using semaglutide for diabetes or weight loss have not documented clinically significant disruption of menstrual cycling or ovarian reserve. The medication is not classified as teratogenic by major regulatory bodies, though it is typically discontinued before conception planning due to limited first-trimester safety data rather than evidence of harm.

Pregnancy Planning While on Semaglutide

Medical guidelines recommend discontinuing semaglutide at least one to two months before attempting conception, even though the drug clears relatively quickly from circulation. This conservative approach reflects the absence of large prospective trials in pregnant patients, not proof of risk. Patients should discuss timing with their healthcare provider and plan a gradual weight-management transition to avoid rapid weight regain during the washout period.

PlexusDx providers work with patients to establish realistic fertility timelines and coordinate care with reproductive specialists when needed. The Precision Peptide Genetic Test can identify individual variations in GLP1R and FTO genes that predict your metabolic response to semaglutide—information that helps customize dosing and duration of therapy before pregnancy planning begins. Starting treatment early allows adequate time to achieve fertility-promoting weight loss before conception attempts.

Safety Data and What Research Actually Shows

The FDA has not identified semaglutide as contraindicated in reproductive planning, but no medication is used during pregnancy unless benefits clearly outweigh risks. Real-world data from hundreds of thousands of semaglutide users shows no unexpected patterns of infertility or miscarriage, though surveillance continues. Women with diabetes using GLP-1 agonists have conceived and delivered healthy infants, yet formal safety registries for weight-loss indication remain limited.

Individuals concerned about reproductive outcomes should not stop semaglutide abruptly without medical guidance. Rapid weight regain and metabolic deterioration can be more harmful to fertility than continuing the medication briefly. PlexusDx recommends transparent conversations with your healthcare team about family-planning goals at the time of treatment initiation, allowing coordinated decision-making that balances weight-loss benefits with reproductive timelines.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Will semaglutide prevent me from getting pregnant?

No. The weight loss semaglutide produces typically improves fertility in people with obesity. The medication is discontinued before conception planning out of caution, not because it causes infertility. Discuss your specific situation with your PlexusDx provider and reproductive health team.

How long should I wait after stopping semaglutide before trying to conceive?

Standard medical practice recommends waiting one to two months after discontinuation, though this may vary based on individual factors. Semaglutide clears from your system within days, but this window allows metabolic stabilization. Your PlexusDx provider can help establish a personalized timeline.

Does the Precision Peptide Genetic Test help with fertility planning?

Yes. PlexusDx's genetic test analyzes variants in GLP1R and FTO genes that influence your weight-loss trajectory and metabolic response. Understanding these pathways helps optimize semaglutide dosing and duration before conception, supporting faster achievement of fertility-promoting weight loss.

Can I use semaglutide while trying to conceive?

Current medical guidelines recommend discontinuing semaglutide before attempting pregnancy due to limited first-trimester data. However, the weight loss achieved on semaglutide significantly improves conception rates in people with obesity. Work with your healthcare team to plan a safe transition off the medication.

What if I regain weight after stopping semaglutide before pregnancy?

Weight regain is a common concern. PlexusDx providers design post-medication maintenance strategies—including nutrition, exercise, and sometimes restart protocols after pregnancy—to sustain fertility-supporting weight. Discuss long-term management goals during your initial consultation.

Related Reading

• Genetic Testing 101 What You Need To Know Before Getting Tested
• What Genetic Factors Determine How Much Sleep You Need Each Night
• Lifemd Ozempic
• Eden Ozempic

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.